OncoMatch/Clinical Trials/NCT06174987
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Is NCT06174987 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies T-DXd for advanced cancer.
Treatment: T-DXd — This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or DS/Astra Zeneca (AZ)-sponsored study (eg. DS8201-A-J101, DS8201-A-U201, DS8201-A-U204, DS8201-A-U207, DS8201-A-U303).
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Metastatic Cancer
Prior therapy
Must have received: DS or DS/AZ alliance study drug — parent study
Currently enrolled in a DS or DS/AZ-sponsored parent study that has met EOS definition
Cannot have received: T-DXd
Exception: off therapy for >18 weeks (126 days) between last dose from parent study and initiation on this study
Participant who has been off T-DXd therapy for >18 weeks (126 days) between the last dose from the parent study and the initiation of study drug administration on this study
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Miami Cancer Institute · Miami, Florida
- Duke University - Trent Center · Durham, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify